NCT05023551 is a EARLY_PHASE1 clinical trial of DSP-0390 in High Grade Glioma, sponsored by Sumitomo Pharma America, Inc..

Who is sponsoring NCT05023551?

NCT05023551 is sponsored by Sumitomo Pharma America, Inc..

What drugs are being tested in NCT05023551?

Interventions in NCT05023551: DSP-0390.

What condition does NCT05023551 study?

NCT05023551 studies High Grade Glioma, Glioblastoma Multiforme.

Is NCT05023551 still recruiting?

NCT05023551 is currently active, enrolled. Last updated 16 September 2025.

Last reviewed 2025-09-16 · How we verify

NCT05023551

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of DSP-0390 in Patients With Recurrent High-Grade Glioma

Active, enrolled EARLY_PHASE1 Last updated 16 September 2025

What this trial tests

EARLY_PHASE1 trial testing DSP-0390 in High Grade Glioma in 39 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

8 September 2021

Primary endpoint
30 September 2026

31 October 2026

Quick facts

Lead sponsor	Sumitomo Pharma America, Inc.
Phase	EARLY_PHASE1
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	39
Start date	8 September 2021
Primary completion	30 September 2026
Estimated completion	31 October 2026
Sites	9 locations across Japan, United States

Drugs / interventions tested

DSP-0390 — full drug profile →

Conditions studied

High Grade Glioma — all drugs for High Grade Glioma →
Glioblastoma Multiforme — all drugs for Glioblastoma Multiforme →

Sponsor

Sumitomo Pharma America, Inc. — full company profile →

Who can join

18 and older, any sex, with High Grade Glioma or Glioblastoma Multiforme. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a study of DSP-0390 in patients with recurrent high grade glioma.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

The potential role and mechanism of circRNA/miRNA axis in cholesterol synthesis.
Chen W, Xu J, Wu Y, Liang B, et al · · 2023 · cited 66× · PMID 37324939 · DOI 10.7150/ijbs.84994
Glioma Stem Cells-Features for New Therapy Design.
Pećina-Šlaus N, Hrašćan R. · · 2024 · cited 7× · PMID 38672638 · DOI 10.3390/cancers16081557
Repurposing Clemastine to Target Glioblastoma Cell Stemness.
Sun MA, Yang R, Liu H, Wang W, et al · · 2023 · cited 2× · PMID 37760589 · DOI 10.3390/cancers15184619
CTNI-68. PHASE I/II STUDY OF MAINTENANCE THERAPY WITH METFORMIN AND TEMOZOLOMIDE FOR TARGETING GLIOBLASTOMA CANCER STEM CELLS
· 2023
CTNI-66. DECODING GLIOBLASTOMA SURVIVAL: UNRAVELING THE PROGNOSTIC POTENTIAL OF OLFACTORY FUNCTION IN A PROSPECTIVE OBSERVATIONAL STUDY
· 2023
CTNI-67. FIRST IN HUMAN STUDY OF DSP-0390, AN ORAL EMOPAMIL BINDING PROTEIN (EBP) INHIBITOR, IN RECURRENT HIGH-GRADE GLIOMA (HGG): PRELIMINARY RESULTS
· 2023
CTNI-65. INVESTIGATING SAFETY AND EFFICACY OF TTFIELDS PRIOR AND CONCOMITANT TO RADIOTHERAPY IN NEWLY DIAGNOSED GLIOBLASTOMA - FIRST RESULTS OF THE PRICOTTF PHASE I/II TRIAL
· 2023
10006-PEDT-1 PEDIATRIC LOWER GRADE GLIOMA SURGERY IN THE ERA OF GENOMIC MEDICINE
· 2023

Verify or expand the search:

Other trials of DSP-0390

Trials testing the same drug.

NCT06636162 — Window of Opportunity Study of DSP-0390 in Gliomas · EARLY_PHASE1 · recruiting

Other recruiting trials for High Grade Glioma

Currently open trials in the same condition.

NCT06333899 — Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion · EARLY_PHASE1 · recruiting
NCT06428045 — STARLITE for Unresectable High-Grade Gliomas · Phase 1 · recruiting
NCT06504381 — DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma · Phase 1, PHASE2 · recruiting
NCT05843253 — Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant · Phase 2 · recruiting
NCT05839379 — Targeted Pediatric High-Grade Glioma Therapy · recruiting

Other Sumitomo Pharma America, Inc. trials

Trials by the same sponsor.

NCT06891885 — A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years · Phase 1, PHASE2 · recruiting
NCT06753331 — A Multicenter Study to Evaluate Safety, Tolerability, and Clinical Responses of DSP-1083 Into Subjects With Parkinson's · Phase 1, PHASE2 · recruiting
NCT06517940 — A Prospective, Observational Study in Adults With Retinitis Pigmentosa (RP) · active not recruiting
NCT07492355 — TP-3654 Food Effect Study · Phase 1 · completed
NCT06037668 — A Randomized, Controlled Study of Two At-Home Self-Guided Virtual Reality Interventions for Adults With Social Anxiety D · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05023551 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sumitomo Pharma America, Inc.
Last refreshed: 16 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05023551.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing